Published DateClear

Start Date

End Date

Category

• Pipeline2

Organizations

• Bausch + Lomb72
• Eyes On Eyecare55
• Alcon, Inc.49
• American Optometric Association38
• Harrow32
• Glaukos30
• Topcon Healthcare26
• Regeneron25
• Aldeyra Therapeutics21
• Coopervision19

Tags

• Clinical Trials2
• AMD1
• Injections1
• Retina1
• Thyroid Eye Disease (ted)1
• Wet Amd1

• Organizations: Innovent Biologics✕

Clear all

Pipeline

Innovent Biologics' wet AMD anti-VEGF meets phase 2 primary endpoint

Intravitreal injection of high-dose IBI302 demonstrates positive long-interval dosing efficacy and safety data.

Pipeline

First patient dosed in phase 2, China-based TED trial

The RESTORE trial is assessing the proptosis responder rate following dosage of IBI311, an IGF-1R monoclonal antibody.